Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pulmonary Disease, Chronic Obstructive 1Pneumonia 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Methylprednisolone 2Etanercept 2Bronchoalveolar Lavage 2ziprasidone 1Zolpidem 1XAV-19 1X-Rays 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Ultrasonography 1Tranexamic Acid 1Tobramycin 1Surveys and Questionnaires 1Spironolactone 1Sodium Bicarbonate 1Sevelamer 1Saline Solution 1Rocuronium 1Ribavirin 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nifedipine 1Nafcillin 1Molindone 1Mass Screening 1Lurasidone Hydrochloride 1Labetalol 1Haloperidol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pneumonia × CIMAvax EGF × Clear all
NCT04298606 2026-03-17

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡